Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion type Assertion NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_head.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion evidence source_evidence_literature NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion SIO_000772 17768113 NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion wasDerivedFrom befree-2016 NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.
- NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion wasGeneratedBy ECO_0000203 NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.